Home / Resources / Videos / AACE 2017 / Robert Rapaport Part 4, New Technology

Robert Rapaport Part 4, New Technology

Jan 26, 2018
 

In part 4 of this Exclusive Interview, Dr. Robert Rapaport talks with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin, Texas about the use of the latest diabetes technology in his practice.

Robert Rapaport, MD is Professor of Pediatrics, Chief of the Division of Pediatric Endocrinology and Diabetes and the Emma Elizabeth Sullivan Professor of Pediatric Endocrinology and Diabetes at Icahn School of Medicine at Mount Sinai, New York. 

Transcript of this video segment:

Steve:  Two years from today when you are at the AACE, and you want to go home so you call a cab.  The cab pulls up and there is no driver in it, it’s a driverless cab.  Are you going to get in that cab?

Dr. Rapaport:  As long as the car is wearing a CGM I will be happy to get in it.

Steve:  The technology has really changed the way we practice medicine.  Google and Dexcom are working on a Band-Aid, CGM, non-invasive.

Dr. Rapaport:  All kinds of things are coming down the pike, which will be really cool along with virtual reality, and by then they will probably have virtual physicians as well.

Steve:  Are you familiar at all with the smart insulins that might be coming down the pike?

Dr. Rapaport:  I am somewhat familiar with them.  Huge advances, better insulins, newer insulins, faster insulins, longer-acting insulin, less peak longer-acting insulins, all of these are very important.  I think, the technology is advancing tremendously, what needs to advance along with it is the understanding as to what makes the patient utilize these things and utilize them to their benefit.

Steve:  Have you ever used in your practice inhaled insulin for a pediatric [patient]?

Dr. Rapaport:  No, we actually never did.  I was a part of the team that evaluated one of the brands of inhaled insulin which did not go very far.  Other forms of insulin would be tremendously important; having non-injectable insulin as a large category is very important.  Non-injectable could be inhaled, which I’m not sure is going all that far, but also topical, buccal insulin, all these things are very important future advances.

Return to the main page.